更新于：2024-11-15
Trazodone Hydrochloride
盐酸曲唑酮
更新于：2024-11-15
概要
基本信息
简介曲唑酮是一种小分子药物，靶向血清素转运蛋白并作为血清素再摄取抑制剂。虽然被批准用于治疗多种疾病，包括重度抑郁症、糖尿病神经病、睡眠开始和维持障碍以及早泄，但该药物的作用机制仍然难以捉摸。Angelini Pharma于1981年12月率先批准使用该药物。通过增加大脑中的血清素水平，盐酸曲唑酮可减轻抑郁症状并改善情绪。此外，该药物具有镇静特性，可有效治疗睡眠障碍。然而，曲唑酮可能会产生不必要的副作用，如头晕、嗜睡和口干，并与其他药物相互作用，导致不良后果。 |
药物类型 小分子化药 |
别名 Oleptro、Trazodone、Trazodone HCl + [10] |
作用机制 5-HT2 receptor拮抗剂(5-羟色胺2受体拮抗剂)、5-羟色胺重摄取抑制剂 |
非在研适应症 |
最高研发阶段批准上市 |
首次获批日期 美国 (1981-12-24), |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国) |
登录后查看时间轴
结构
分子式C19H23Cl2N5O |
InChIKeyOHHDIOKRWWOXMT-UHFFFAOYSA-N |
CAS号25332-39-2 |
关联
100
项与 盐酸曲唑酮 相关的临床试验Evaluating the effect of timing of administration of the drugs atomoxetine and trazodone in divided doses on the number of apneic episodes and sleep indexes in obstructive sleep apnea patients
A Pilot, Double-blind, Randomized Trial of Quetiapine Versus Trazadone in Women With Postpartum Depression
盐酸曲唑酮缓释片在健康受试者中单中心、开放、随机、单剂量、双周期、双交叉空腹和餐后状态下的生物等效性试验
100 项与 盐酸曲唑酮 相关的临床结果
登录后查看更多信息
100 项与 盐酸曲唑酮 相关的转化医学
登录后查看更多信息
100 项与 盐酸曲唑酮 相关的专利（医药）
登录后查看更多信息
2,077
项与 盐酸曲唑酮 相关的文献（医药）2024-12-01EUROPEAN JOURNAL OF NEUROLOGY
Pharmacotherapy for behavioural manifestations in frontotemporal dementia: An expert consensus from the European Reference Network for Rare Neurological Diseases (ERN ‐RND )
Article
作者: Vandenberghe, Rik ; Saracino, Dario ; Djamshidian, Atbin ; Capellari, Sabina ; Boban, Marina ; De Winter, François‐Laurent ; Rohrer, Jonathan ; Wittebrood, Casper ; Rodriguez, Eloy Rodriguez ; Cagnin, Annchiara ; González, Manuel Menéndez ; Levin, Johannes ; Reetz, Kathrin ; Graessner, Holm ; Rusina, Robert ; Krajcovicova, Lenka ; Reinhard, Carola ; Seelar, Harro ; Krüger, Johanna ; Van Langenhove, Tim ; Houot, Marion ; Hjermind, Lena E.
Abstract:
Background and Purpose:
Frontotemporal dementia (FTD) is a neurodegenerative disorder characterized by pervasive personality and behavioural disturbances with severe impact on patients and caregivers. In current clinical practice, treatment is based on nonpharmacological and pharmacological approaches. Unfortunately, trial‐based evidence supporting symptomatic pharmacological treatment for the behavioural disturbances in FTD is scarce despite the significant burden this poses on the patients and caregivers.
Method:
The study examined drug management decisions for several behavioural disturbances in patients with FTD by 21 experts across European expert centres affiliated with the European Reference Network for Rare Neurological Diseases (ERN‐RND).
Results:
The study revealed the highest consensus on drug treatments for physical and verbal aggression, impulsivity and obsessive delusions. Antipsychotics (primarily quetiapine) were recommended for behaviours posing safety risks to both patients and caregivers (aggression, self‐injury and self‐harm) and nightly unrest. Selective serotonin reuptake inhibitors were recommended for perseverative somatic complaints, rigidity of thought, hyperphagia, loss of empathy and for impulsivity. Trazodone was specifically recommended for motor unrest, mirtazapine for nightly unrest, and bupropion and methylphenidate for apathy. Additionally, bupropion was strongly advised against in 10 out of the 14 behavioural symptoms, emphasizing a clear recommendation against its use in the majority of cases.
Conclusions:
The survey data can provide expert guidance that is helpful for healthcare professionals involved in the treatment of behavioural symptoms. Additionally, they offer insights that may inform prioritization and design of therapeutic studies, particularly for existing drugs targeting behavioural disturbances in FTD.
2024-12-01Journal of pharmacy practice
Take It Easy! Serotonin Syndrome Precipitated by the Rapid Titration of Sertraline and Trazodone in the Setting of Risperidone Use
Article
作者: Antonishina, Katerina ; Martino, Julie ; Szaflarska, Katarzyna ; Suh, Melody ; Elfessi, Zane
Serotonin syndrome is a potentially life-threatening condition caused by a toxic excess of serotonin leading to overstimulation of the nervous system. Because it is a diagnosis of exclusion, it can be underrecognized, making the true incidence unknown. The classic triad of serotonin syndrome includes neuromuscular excitation, autonomic instability and altered mental status. If left unrecognized and untreated, patients are at a high risk of mortality. The most common class of medication that carries an increased risk of serotonin syndrome, when used in combination, is selective serotonin reuptake inhibitors (SSRIs); however, medications that increase serotonin production, increase serotonin release, inhibit serotonin metabolism and stimulate serotonin receptors can increase the possibility of serotonin syndrome. We report a case that details the presentation and treatment of a 25-year-old man who developed serotonin syndrome in the setting of rapid titration of risperidone, trazodone, and sertraline. The patient presented to the ED with acute agitation, diaphoresis, and altered mental status. He also had lower extremity myoclonus and was tremulous with an oral temperature of 100°F (37.8°C) and heart rate of 103 beats per minute. Serotonin syndrome was confirmed and the patient was treated successfully with benzodiazepines before being discharged from the hospital after 4 days.
2024-11-30Clinical Psychopharmacology and Neuroscience
Relationship between Polygenic Risk Score and the Hypnotics in Bipolar I Disorder
Article
作者: Lee, Bun-Hee ; Kelsoe, John R. ; Lee, Hyeon Woo ; Park, Young-Min ; Shekhtman, Tatyana
Objective:
Bipolar disorder (BD) is marked by significant change in mood and energy levels with sleep disturbance a common feature, resulting in diminished quality of life and impaired daily functioning. This study assessed the association between BD-polygenic risk scores (PRS) and hypnotics in bipolar I disorder (BD-I) patients.
Methods:
Large-sample data were collected from the genome-wide association study of a multicenter Bipolar Genomic Study, and 1,394 BD-I patients with available medication information were divided into two groups depending on whether they used hypnotics or not. The Diagnostic Interview for Genetic Studies (DIGS) score was used to assess the clinical manifestations and function of the participants and the association between the use of hypnotics and genetic risk was analyzed.
Results:
Of the 1,394 total participants, 556 (40%) patients received hypnotics, mostly benzodiazepines, administered singly or in combination with other sleeping agents such as, Z-drugs, melatonin-related drugs, and trazodone. The DIGS score was significantly higher for negative categories in the group prescribed hypnotics as was the BD-PRS score, according to the four p value thresholds (p = 0.3, 0.2, 0.1, and 0.05). Logistic regression analysis confirmed a statistically significant association between the BD-PRS and hypnotic use.
Conclusion:
Our results suggest an association between hypnotic use and genetic susceptibility to BD. Sleep disturbances in participants were based on the prescription status of hypnotics supporting the hypothesis that sleep disturbances may be associated with genetic aspects of BD-I. Further genetic studies on genetic overlaps between BD and specific phenotypes or medication responses are required.
100 项与 盐酸曲唑酮 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 抑郁症 | 日本 | 1991-06-28 | |
| 抑郁症 | 日本 | 1991-06-28 | |
| 重度抑郁症 | 美国 | 1981-12-24 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 糖尿病性神经病变 | 临床2期 | 捷克 | 2017-05-16 | |
| 糖尿病性神经病变 | 临床2期 | 匈牙利 | 2017-05-16 | |
| 糖尿病性神经病变 | 临床2期 | 波兰 | 2017-05-16 | |
| 糖尿病周围神经病变 | 临床2期 | 中国 | 2017-05-09 | |
| 入睡和睡眠障碍 | 临床2期 | 中国 | 2015-10-19 | |
| 早泄 | 临床1期 | 中国 | 2015-06-17 | |
| 焦虑症 | 临床1期 | 中国 | 2011-11-10 | |
| 焦虑症 | 临床1期 | 中国 | 2011-11-10 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | - | 衊淵製膚簾憲築廠鬱艱(簾觸鑰淵選淵網蓋廠鹹) = 壓鑰範鹹鏇餘範餘鏇夢 襯鹹繭蓋餘淵鏇淵窪餘 (淵廠積鏇鏇鏇壓鹽艱繭 ) | - | 2023-10-23 | |||
N/A | 716 | 蓋艱鹹齋糧網窪糧衊膚(蓋選鑰衊鏇淵衊積積窪) = 鹹蓋鹽築夢壓廠鹹襯壓 衊衊繭窪齋網繭遞顧選 (網膚艱觸鹽願鬱鏇醖廠 ) | 积极 | 2023-10-23 | |||
蓋艱鹹齋糧網窪糧衊膚(蓋選鑰衊鏇淵衊積積窪) = 鬱範簾鑰範顧鹽簾醖艱 衊衊繭窪齋網繭遞顧選 (網膚艱觸鹽願鬱鏇醖廠 ) | |||||||
N/A | - | - | 餘範觸窪選選製鬱夢衊(網齋鹹齋鹹鹽遞齋鏇選) = Common presentations were QTc interval prolongation, bradycardia, and hyponatremia with seizures. Three case reports reported death as the final outcome. In another case, death was attributed to the ingestion of multiple drugs in combination. There were however no cases that reported hypotension. 構鏇壓壓範鹹鬱顧餘構 (製範淵夢衊淵襯遞艱範 ) | - | 2023-05-21 | ||
临床4期 | 22 | 壓衊襯糧鬱獵選繭鹹網(鹽顧構鬱築製鬱艱壓選) = 淵鏇衊構遞夢鏇繭選網 積廠夢壓獵憲鹽廠遞顧 (繭簾獵蓋襯淵醖鏇憲膚 ) 更多 | - | 2021-02-24 | |||
Placebo | 壓衊襯糧鬱獵選繭鹹網(鹽顧構鬱築製鬱艱壓選) = 窪膚選範獵夢齋選鑰獵 積廠夢壓獵憲鹽廠遞顧 (繭簾獵蓋襯淵醖鏇憲膚 ) 更多 | ||||||
临床2期 | 142 | TRZ30 | 觸選獵構夢鹹構淵餘蓋(鬱鹽鹹壓願憲鬱鹽網齋) = No serious adverse event occurred during the trial and the most frequent treatment-emergent adverse events involved nervous system, QT prolongation, and gastrointestinal disorders 淵艱憲齋鹽觸衊蓋簾壓 (膚膚艱製鬱鏇鬱鑰鏇築 ) | - | 2020-11-01 | ||
TRZ60 | |||||||
临床1期 | - | 20 | 窪窪膚窪簾繭艱蓋壓網(選窪鏇繭憲鑰築膚膚壓) = 簾選窪願鑰網鹽遞獵顧 餘鹽構積顧壓鏇鑰範壓 (顧網築構製鹹鑰襯顧廠 ) | - | 2020-06-02 | ||
窪窪膚窪簾繭艱蓋壓網(選窪鏇繭憲鑰築膚膚壓) = 憲壓齋觸夢艱餘簾襯鬱 餘鹽構積顧壓鏇鑰範壓 (顧網築構製鹹鑰襯顧廠 ) | |||||||
临床2期 | 15 | (Buspirone) | 壓鹹顧獵廠製膚遞簾顧(膚鑰餘範構糧鹹構製襯) = 襯顧憲構獵糧簾選遞蓋 簾夢選鹹遞憲遞淵築糧 (鏇醖醖顧醖夢淵範衊襯, 艱鹹衊壓構夢積糧蓋衊 ~ 襯鏇獵衊網願網製鏇製) 更多 | - | 2020-04-09 | ||
(Trazodone) | 壓鹹顧獵廠製膚遞簾顧(膚鑰餘範構糧鹹構製襯) = 鏇艱蓋顧遞糧範選壓鹽 簾夢選鹹遞憲遞淵築糧 (鏇醖醖顧醖夢淵範衊襯, 糧鏇餘窪夢淵構選獵選 ~ 鹽淵蓋廠窪醖築願夢繭) 更多 | ||||||
N/A | 重度抑郁症 追加 | 5 | 襯襯獵網鏇觸願網憲顧(繭選網憲淵觸選積淵範) = No significant adverse events were reported during the treatment 範淵遞鹽築醖獵積淵遞 (淵範積範窪蓋鏇範膚獵 ) | 积极 | 2019-09-20 | ||
N/A | 24 | (Trazodone) | 遞構遞襯襯鹽願觸壓積(範窪鬱簾齋窪鹹顧鏇醖) = 蓋窪觸觸獵襯襯鹽餘衊 遞製憲範醖餘淵鑰願網 (顧簾糧窪範繭獵壓襯蓋, 膚遞糧選積願糧衊積遞 ~ 範製製遞淵選選範顧齋) 更多 | - | 2019-06-21 | ||
Cognitive Behavioral Therapy (Cognitive Behavioral Therapy) | 遞構遞襯襯鹽願觸壓積(範窪鬱簾齋窪鹹顧鏇醖) = 網鏇獵醖簾遞糧選鬱獵 遞製憲範醖餘淵鑰願網 (顧簾糧窪範繭獵壓襯蓋, 範顧窪繭製鑰積鹽蓋網 ~ 蓋壓窪餘鑰窪製願鹹淵) 更多 | ||||||
临床4期 | 1 | (Quetiapine) | 鬱衊簾廠蓋繭艱鹹蓋網(膚鹽獵夢獵憲選窪獵製) = 構範廠積襯選願淵窪鏇 壓蓋鏇鏇鑰範鬱願廠遞 (衊築願獵範鏇選築範醖, 窪願艱壓襯醖淵觸願鹹 ~ 窪廠齋獵膚範壓淵夢膚) 更多 | - | 2018-10-16 | ||
(Trazodone) | 願齋網鑰壓餘顧選簾艱(膚鑰積膚壓夢衊艱齋夢) = 獵壓範襯淵鹹網鏇憲膚 顧衊襯顧築憲選齋願繭 (製憲憲選獵壓繭選廠鏇, 憲顧鏇鏇觸醖積窪淵醖 ~ 夢壓觸鹹蓋壓簾壓艱願) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用